 | |
| Clinical data | |
|---|---|
| Other names | ALEPH-4; 4-Isopropylthio-2,5-dimethoxyamphetamine; 2,5-Dimethoxy-4-isopropylthioamphetamine; 4-iPrS-DMA |
| Routes of administration | Oral[1] |
| Drug class | Serotonergic psychedelic;Hallucinogen |
| ATC code |
|
| Pharmacokinetic data | |
| Duration of action | 12–20 hours[1] |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C14H23NO2S |
| Molar mass | 269.40 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Aleph-4, orALEPH-4, also known as4-isopropylthio-2,5-dimethoxyamphetamine, is apsychedelic drug of thephenethylamine,amphetamine, andDOx families.[1] It is one of theAleph series of compounds.[1] In his bookPiHKAL (Phenethylamines I Have Known and Loved),Alexander Shulgin lists Aleph-4's dose as 7 to 12 mgorally and itsduration as 12 to 20 hours.[1] The effects of Aleph-4 have been reported to includeclosed-eyeimagery, enhancedvisual appreciation,emotional changes, andphysicalside effects andtoxicity indications, among others.[1] One of the reports remarked that it was "one of the most profound and deep learning experiences" they had had.[1] However, Shulgin was unwilling to push the dose higher than 12 mg due to toxicity concerns.[1] Thechemical synthesis of Aleph-4 has been described.[1] Aleph-4 was first described in thescientific literature by Shulgin,David E. Nichols,Peyton Jacob III, and other colleagues in 1978.[2] Subsequently, it was described in greater detail by Shulgin inPiHKAL in 1991.[1] The drug was encountered as a noveldesigner drug inJapan in 2009.[3][4]
